COLL COLLEGIUM PHARMACEUTICAL, INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1267565 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY7.7%
TTM net income YoY-34.7%
TTM EPS YoY-37.9%
Revenue 3-yr CAGR14.2%
Net income 3-yr CAGR61.8%
Margins
Gross margin59.0%
Operating margin15.2%
Net margin4.7%
FCF margin41.3%
EBITDA margin15.7%
Returns
ROE13.4%
ROA2.1%
ROIC (approx.)81.3%
Asset turnover0.44x
Leverage & solvency
Liabilities / assets85.9%
Debt / equity0.00x
Current ratio1.01x
Interest coverage1.62x
Cash quality & payout
Operating cash flow / net income8.86x
Accruals ratio-16.2%
Payout ratio—
Capex / revenue0.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $780.57M | $631.45M |
| Cost of revenue | $317.31M | $254.10M |
| Gross profit | $463.26M | $377.34M |
| R&D expense | — | $0 |
| SG&A expense | $284.80M | $210.36M |
| Operating income | $179.64M | $169.90M |
| Interest expense | $82.31M | $73.97M |
| Pretax income | $92.62M | $98.57M |
| Income tax | $29.75M | $29.38M |
| Net income | $62.87M | $69.19M |
| EBITDA | $183.82M | $173.75M |
| EPS (basic) | 1.98 | 2.14 |
| EPS (diluted) | 1.73 | 1.86 |
| Weighted avg. shares (diluted) | 39.70M | 40.42M |
| Balance sheet | ||
| Cash & equivalents | $231.25M | $96.61M |
| Short-term investments | $155.43M | $92.20M |
| Receivables | $211.33M | $228.54M |
| Inventory | $40.91M | $35.56M |
| Current assets | $691.41M | $482.26M |
| PP&E, net | $12.01M | $14.33M |
| Goodwill | $145.93M | $162.33M |
| Intangibles | $669.51M | $891.40M |
| Total assets | $1.66B | $1.66B |
| Current liabilities | $440.03M | $509.51M |
| Total liabilities | $1.36B | $1.43B |
| Shareholders' equity | $301.68M | $228.84M |
| Shares outstanding | 31.71M | 31.44M |
| Cash flow statement | ||
| Operating cash flow | $329.32M | $204.98M |
| Capital expenditure | $1.74M | $1.65M |
| Free cash flow | $327.58M | $203.33M |
| Investing cash flow | -$63.53M | -$287.76M |
| Financing cash flow | -$110.25M | -$60.60M |
| Depreciation & amortization | $4.18M | $3.86M |
| Stock-based compensation | $41.91M | $32.40M |
| Share buybacks | $25.10M | $60.02M |
Free plan shows the latest 2 periods; Pro shows all 13 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.